Medicines Co. (MDCO) Tops Q3 EPS by 30c

Medicines Co. (NASDAQ: MDCO) reported Q3 EPS of $0.18, $0.30 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $172.4 million versus the consensus estimate of $188.3 million.

Adjusted net income was $29.3 million, or $0.47 per share, for the third quarter 2013.

For earnings history and earnings-related data on Medicines Co. (MDCO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Quantum BioPharma gets FDA nod for Lucid-MS Phase 2 MS trial
• ACCO Brands to buy European peripherals brand Trust for ~$100M revenue